BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the 18th Annual BIO CEO & Investor Conference in New York City on Monday, February 8, 2016, at 9:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible from the Investor Relations section of the Aimmune website at www.aimmune.com. A replay of the webcast will be available for 14 days following the event.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other food allergies. The company’s characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. In early 2016, Aimmune Therapeutics initiated the Phase 3 PALISADE trial of its lead product, AR101 for the treatment of peanut allergy, one of the most common food allergies. AR101 has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. For more information, please see www.aimmune.com.